Roundtable Discussion: Understanding Investor Perspectives on Exosome Therapeutics to Navigate Risk Reward Clinical Validation & Platform Scalability in a Growing Field
- Exploring how investors assess scientific credibility, clinical maturity, and differentiation within a rapidly evolving exosome landscape
- Debating key risk factors including regulatory uncertainty, manufacturing scalability, and reproducibility of exosome-based products
- Identifying investment catalysts such as early clinical readouts, strategic partnerships, and platform validation across multiple indications